The Chief AI Officer Mandate

An academic medical center with 600 beds buys an AI tool from a national vendor to predict sepsis. A CIO works on a plan to integrate the tool with the EHR. A chief medical officer signs a contract to let the sepsis prediction tool to output to the inpatient workflow. The information security team clears the technical review for the integration. The business associate agreement is signed by the legal team. A clinical operations director develops an order-set logic to use a scoring system that triggers a nursing alert. After six months, the tool begins to drift. The number of false alerts increases significantly. Nurses on the unit begin to override the alerts without a documented clinical reason. One unit files a report for a near-miss event, where consistent sepsis was hidden because of alert fatigue.

The post-event review begins, and each report comes in one at a time. Each report begins with a response that can be justified. The CIO can legally demonstrate that the integration is operating correctly. CMIO can demonstrate that the order-set logic was signed and is operational at go-live. Information security team can demonstrate that there was no data breach. The legal team confirms a contract was signed correctly. The vendor demonstrates the model is operational within the boundaries of the model's training data. Each report is consistent from the internal perspective. However, each report is completely self-sufficient and does not address the cause of alert repeating that led to the near-miss event. The model remains active because no person in the organizational hierarchy can stop, retrain, renegotiate, or be obligated to report the model's use to the committee. That vacant position is the Chief AI Officer.

The CIO is the owner of the infrastructure. The CMIO is responsible for clinical informatics. The CISO is responsible for information security. The CDO is responsible for data. Each of these positions impacts some part of the model lifecycle. However, none are responsible for the model lifecycle. The model lifecycle calls for an entirely different type of leadership seat than the EHR era produced, and most health systems are still struggling to find that seat in an org chart created for systems that were set up once and ran without any behavioral changes.

The American Hospital Association, in the 2024 edition of its Trustees Toolkit about the use of AI in health care, named the oversight of the senior-most leadership role of AI as the most significant remaining gap in the deployment of AI across health systems. The ECRI Institute counted poor governance of AI use in healthcare as its fifth most critical health tech hazard on its 2024 list, and then counted AI as the most critical hazard on its 2025 list in regards to AI and the healthcare app. The ONC, in the HTI-1 final rule, designated senior leadership role definition as the most important of all architectural choices. The AHRQ patient safety reports argued for the post verification of absolute safety combined with constant scrutiny of changes.

An organizational chart suited to the electronic health record (EHR) era won't last long. EHRs are often set and forget. Models are not. Drift is always in wait, as the patient population, procedural documentation, and upstream data sources, to name a few, inevitably transform. Re-training cycles cause drift, yet are seldom mentioned in vendor release notes. Data and EHRs change, often unpredictably. The model changes each time the EHR and data sources change. Zeroth continuous process define and scope it. The position must be able to oversee the process in full, one piece at a time. Only then can the system be free of the void noted in the sepsis-tool report.

There are six responsibilities associated with the CAIO mandate. First, they are tasked with defining the portfolio strategy. This involves deciding which models the health system will deploy, the clinical or operational rationale, model retirement dates, and rotational deployment. The second responsibility involves pre-deployment analyses that dissect the results by equity-stratified subgroups and use local data instead of vendor data. Third is the tracking of model drift, performance, and equity outcomes. This must happen on a documented schedule, and the framework must survive staff changes. Fourth is the negotiating of the vendor contract terms, including model change, model pause, and performance shift procedures, and the vendor's role when the model fails. The fifth responsibility involves operational and clinical workforce upskilling so that staff are better equipped to use the models the system employs rather than work around the models. Finally, the CAIO must decide what, when, and how deeply they report to the Board. The CAIO must also determine which decisions are to be made exclusively by the Board.

Splitting these six per the request across four senior leaders in absence of a single answer-giver is not feasible. In describing the combining of senior leadership required in this role, the Coalition for Health AI Blueprint v1.0 has commented on portfolio coherence, lifecycle guardianship, and board-level reporting. In the American Medical Association augmented intelligence policy, the need is expressed for a defined point of escalation for AI 'misfiring' behaviors, and that point of escalation cannot be a committee. CAIO has been defined by the American Hospital Association to be the solution to the AI oversight dilemma the board has developed and begun to ask. The Robert J. Margolis Institute for Health Policy at Duke University has discussed the frameworks of organizational constructs that health systems are developing for central AI governance, the CAIO construct being the most defensible.

A working rhythm is also a prerequisite of the CAIO mandate. Drift goes and is undetected in the absence of a monthly portfolio review. Having a quarterly reporting to the board that has CAIO oversight is not the same as having the CAIO in the oversight committee. Having a defined pathway for escalation for reporting that is documented addresses accountability and the proposed system. Health systems that are attempting to recruit CAIO while also not providing necessary rhythm will discover that the role will shift to being a function of the individual that is recruited to the position, and when no longer held by that individual, the function will cease.

The CAIO boundary with the CMIO is the most constraining. CMIOs have most control over the model clinician interface, and CMIOs build strong, direct, and personal relationships with clinicians. CAIOs do not take CMIOs positions. CAIOs will take over portfolio-related responsibilities that the CMIO did not have the time to do, while maintaining the CMIO's primary control over the design of clinical workflows. The first proving of strength is the first model decision. This will determine the limits of the authority the CAIO will have at the time of the next model decision. The failure to gain control over the AI committees precipitated the design of the Coalition for Health AI and Blueprint v1.0. This pattern has not changed.

Next is information security. Health system CISOs have spent the last fifteen years building defense strategies around ransomware, identity, and exfiltration. AI presents a new type of attack, one for which defense strategies have not yet been built. Adversarial examples and prompt injections bypass SIEM and breach detection. Model exfiltration goes unnoticed because it is treated as ordinary and acceptable API use. Supply chain attacks on foundation models use building blocks that the security team chose for a different purpose. The risk of building blocks must now be integrated into the existing model security framework. The Coalition for Health AI Blueprint v1.0 puts model security and information security on a balanced policy stack, and very few health systems have put these into practice. The AI security incident that will first receive a policy response will be the one that is most difficult to justify when coupled with a public response. This is in direct contrast to the policy response that will be easiest to justify.

The CFO meeting has a new format. By 2026, CFOs have seen multiple AI vendor presentations and learned to mentally adjust the vendor's projected AI cost savings by a factor of 2 to 3 before the AI vendor's first slide shows. A senior AI leader relies on the AI vendor's case for the meeting and has to contend with the learned discounts of CFOs before the first slide closes. The case that will convince the CFO includes parts that the vendor will likely leave out. These include the costs when the patient population changes and the costs associated with active model oversight, combined with the costs associated with the real, fully supportive organization with advanced skills added. The Robert J. Margolis Institute work on strategic AI committee shows that CFOs have a better chance of surviving their first year on a committee when integrated finance is present as a committee input. CFOs that see a senior AI leader make three accurate forecasts become their best advocates. That advocacy is what extends the role to the next budget cycle.

AI conversations typically overlook clinical quality, the most consequential factor when it malfunctions. Chief Quality Officers incorporate safety event reviews to include medication errors, diagnostic delays, and surgical errors. Joint Commission RCA2 methodology places the human, technological, and procedural gaps as causal, although separable. AI errors do not fit within causal separable layers. Unlike an AI error, a medication error may entail a syringe, label, and pharmacist note. An AI error would include a model output, a data pipeline, and the clinician who viewed the output and subsequently took action. A CQO who references their existing methodology and treats an AI event stops a layer short of the true cause. ECRI Institute highlighted a dearth of analysis of the post-deployment gap when it ranked AI as the highest hazard for 2025. Bridging the gap requires the CAIO and the CQO to investigate together, with equal authority, a condition most health systems have not yet established.

The AHA Trustee's Toolkit on AI highlighted the senior AI question for boards for 2024 and provided four scoping decisions to consider. These decisions are where the role sits with respect to the CIO and CMO, where the role reports to, what the role owns in writing, and what budget the role has. These four decisions scaffold the stature appropriately. The role enters a defined trajectory of diminishing stature if any one of the scoped decisions is wrong. A title combined with no budget creates a reviewer. The role is a seat with no decision-making authority on the projects to be funded because the title and budget impels a request to be funded. Reporting through the CIO, the seat becomes a project manager. A role that skips the board line becomes a consultant. The workforce is unable to give the role the latitude to escalate requests, thus they stop listening. Each health system taking one of the scoping decisions has spent two years in recovery as the workforce has diminished in confidence to the system after witnessing the first year and describing the seat as unfulfilling.

The actions of an initial holder during the first quarter influences the subsequent three years. Chiefs who take the time to clarify and publish the inherited portfolio, lifecycle policy, board cadence, and escalation path during the first quarter, will come to the first quarterly review with documents and artifacts that the rest of the organization can engage with. Those who use the first quarter for meetings, come to the same review with little more than expressed intentions. After nine months, the artifacts will have either been created and visible to the workforce, or notably absent, and the workforce will make their determination about the hiring versus functional purpose of the title, all without an official deliberation or discussion. Coalition for Health AI Blueprint v1.0 states lifecycle ownership comes before all else, and artifacts from the first quarter are provisional operations evidence that lifecycle ownership is present.

Transitioning from oversight to creation, the focus will shift from what should not occur, to who is accountable when things go wrong. Budget, access to the board, and a charter will be the anchors during year one. Depending on when and where the decision gets made, the reports will continue to close without answers and nobody will be authorized to change any of the shifting patterns. ECRI Institute identified the same gap when AI made it to the top of their 2025 hazard list.

This edition draws on positions from the American Hospital Association 2024 Trustees Toolkit on AI in health care, ECRI Institute Top 10 Health Technology Hazards reports for 2024 and 2025, the ONC HTI-1 final rule and accompanying technical materials, AHRQ patient safety publications on pre-deployment validation and post-deployment monitoring, the American Medical Association augmented intelligence policy, the Coalition for Health AI Blueprint v1.0, NIST AI Risk Management Framework 1.0, the Joint Commission RCA2 methodology, and the Robert J. Margolis Institute for Health Policy at Duke University 2024 publication on AI oversight structures in health systems. Related editions: Issue 39 (Your Board Will Ask About AI. The Question Will Come Too Late.), Issue 40 (The Incident Response Fallacy), Issue 41 (Where Responsibility Breaks Down), and Issue 42 (The Innovation Tax).